Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

ClinicalTrials.gov ID: NCT05137236

Public ClinicalTrials.gov record NCT05137236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates. The main goal of Part B of this study is to assess the safety, reactogenicity, and immunogenicity of the mRNA-1283.529 booster vaccine candidate.

Study identification

NCT ID
NCT05137236
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ModernaTX, Inc.
Industry
Enrollment
540 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2021
Primary completion
Mar 22, 2023
Completion
Mar 22, 2023
Last update posted
Jul 16, 2025

2021 – 2023

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
MedPharmics, LLC Phoenix Arizona 85015-1105
Research Centers of America Hollywood Florida 33024-2709
Precision Clinical Research Sunrise Florida 33351-7311
Tekton Research Chamblee Georgia 30341
MedPharmics Metairie Louisiana 70006
UMass Memorial Medical Center Worcester Massachusetts 01655-0002
Clinical Research Institute, Inc - CRN Minneapolis Minnesota 55402-2700
Meridian Clinical Research (Nebraska) Lincoln Nebraska 68510
MedPharmics, LLC. - Albuquerque Albuquerque New Mexico 87102-3876
Rochester Clinical Research, Inc. Rochester New York 14609
CTI Clinical Research Center Cincinnati Ohio 45212
Meridian Clinical Research (Cincinnati) Cincinnati Ohio 45246-2316
Aventiv Research Inc Columbus Ohio 43213-6517
Coastal Carolina Research Center North Charleston South Carolina 29405-4986
ACRC Trials Frisco Texas 75033-4135
Ventavia Research Group Houston Texas 77008
Health Research of Hampton Roads Inc. Newport News Virginia 23606-4537

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05137236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05137236 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →